Antimycin A induced cardioprotection is dependent on pre-ischemic p38-MAPK activation but independent of MKK3

Journal of Molecular and Cellular Cardiology

Volumn 39, Issue 4, 2005, Pages 709-717

  Kabir, Alamgir M N ^a   Cao, Xuebin ^a   Gorog, Diana A ^a   Tanno, Masaya ^a   Bassi, Rehka ^a   Bellahcene, Mohamed ^a   Quinlan, Roy A ^b   Davis, Roger J ^c   Flavell, Richard A ^d   Shattock, Michael J ^a   Marber, Michael S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b DURHAM UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimycin A; Hsp27; p38 MAPK; SB203580

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTIMYCIN A1; ANTIOXIDANT; FREE RADICAL; HEAT SHOCK PROTEIN 27; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; TIOPRONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISOLATED HEART; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; REPERFUSION;

ANIMALS; ANTIMYCIN A; CARDIOTONIC AGENTS; ENZYME ACTIVATION; MALE; MAP KINASE KINASE 3; MICE; MICE, INBRED STRAINS; MYOCARDIAL REPERFUSION INJURY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

MURINAE;

EID: 24944498878     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2005.07.012     Document Type: Article

References (35)

1. C.E. Murry, R.B. Jennings, and K.A. Reimer Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium Circulation 74 1986 1124 1136
2. D.K. Das, R.M. Engelman, and N. Maulik Oxygen free radical signaling in ischemic preconditioning Ann. N. Y. Acad. Sci. 874 1999 49 65
3. Y. Yue, M. Krenz, M.V. Cohen, J.M. Downey, and S.D. Critz Menadione mimics the infarct-limiting effect of preconditioning in isolated rat hearts Am. J. Physiol. Heart Circ. Physiol. 281 2001 590 595
4. S. Sanada, M. Kitakaze, P.J. Papst, K. Hatanaka, H. Asanuma, and T. Aki Role of phasic dynamism of p38 mitogen-activated protein kinase activation in ischemic preconditioning of the canine heart Circ. Res. 88 2001 175 180
5. E. Marais, S. Genade, B. Huisamen, J.G. Strijdom, J.A. Moolman, and A. Lochner Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion J. Mol. Cell. Cardiol. 33 2001 769 778
6. P.A. Eyers, I.P. Van den, R.A. Quinlan, M. Goedert, and P. Cohen Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580 FEBS Lett. 451 1999 191 196
7. P. Liao, D. Georgakopoulos, A. Kovacs, M. Zheng, D. Lerner, and H. Pu The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy Proc. Natl. Acad. Sci. USA 98 2001 12283 12288
8. L.E. Lemke, L.J. Bloem, R. Fouts, M. Esterman, G. Sandusky, and C.J. Vlahos Decreased p38 MAPK activity in end-stage failing human myocardium: p38 MAPK alpha is the predominant isoform expressed in human heart J. Mol. Cell. Cardiol. 33 2001 1527 1540
9. Y.M. Liu, G.Y. Yin, J. Surapisitchat, B.C. Berk, and W. Min Laminar flow inhibits TNF-induced ASK1 activation by preventing dissociation of ASK1 from its inhibitor 14-3-3 J. Clin. Invest. 107 2001 917 923
10. S.K. Hanks, and T. Hunter Protein kinases 6. The eukaryotic portein-kinase superfamily - kinase (catalytic) domain-structure and classification FASEB J. 9 1995 576 596
11. Y. Wang, S. Huang, V.P. Sah, J. Ross, J.H. Brown, and J. Han Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen activated protein kinase family J. Biol. Chem. 273 4 1998 2161 2168
12. C.I. Chang, B. Xu, R. Akella, M.H. Cobb, and E.J. Goldsmith Crystal structures of MAP kinase p38 complexed to the Docking sites on its nuclear substrate MEF2A and activator MKK3b Mol. Cell 9 2002 1241 1249
13. H.E. Hoover, D.J. Thuerauf, J.J. Martindale, and C.C. Glembotski Alpha B-crystallin gene induction and phosphorylation by MKK6-activated p38. A potential role for alpha B-crystallin as a target of the p38 branch of the cardiac stress response J. Biol. Chem. 275 2000 23825 23833
14. J.J. Martindale, J.A. Wall, D.M. Martinez-Longoria, P. Aryal, H.A. Rockman, and Y. Guo Overexpression of mitogen-activated protein kinase kinase 6 in the heart improves functional recovery from ischemia in vitro and protects against myocardial infarction in vivo J. Biol. Chem. 280 2005 669 676
15. M. Tanno, R. Bassi, D.A. Gorog, A.T. Saurin, J. Jiang, and R.J. Heads Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia Circ. Res. 93 2003 254 261
16. M. Wysk, D.D. Yang, H.-T. Lu, R.A. Flavell, and R.J. Davis Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for tumour necrosis factor induced cytokine expression Proc. Natl. Acad. Sci. USA 96 1999 3763 3768
17. C.C. Hsieh, and J. Papaconstantinou The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid Mech. Ageing Dev. 123 2002 1423 1435
18. J. Duranteau, N.S. Chandel, A. Kulisz, Z. Shao, and P.T. Schumacker Intracellular signaling by reactive oxygen species during hypoxia in cardiomyocytes J. Biol. Chem. 273 1998 11619 11624
19. A. Kulisz, N. Chen, N.S. Chandel, Z. Shao, and P.T. Schumacker Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes Am. J. Physiol. Lung Cell. Mol. Physiol. 282 2002 1324 1329
20. A.T. Saurin, D.J. Pennington, N.J. Raat, D.S. Latchman, M.J. Owen, and M.S. Marber Targeted disruption of the protein kinase C epsilon gene abolishes the infarct size reduction that follows ischaemic preconditioning of isolated buffer-perfused mouse hearts Cardiovasc. Res. 55 2002 672 680
21. D.A. Gorog, M. Tanno, A.M. Kabir, G.S. Kanaganayagam, R. Bassi, and S.G. Fisher Varying susceptibility to myocardial infarction among C57BL/6 mice of different genetic background J. Mol. Cell. Cardiol. 35 2003 705 708
22. C.P. Baines, M. Goto, and J.M. Downey Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium J. Mol. Cell. Cardiol. 29 1997 207 216
23. R. Carroll, V.A. Gant, and D.M. Yellon Mitochondrial K(ATP) channel opening protects a human atrial-derived cell line by a mechanism involving free radical generation Cardiovasc. Res. 51 2001 691 700
24. B. Ge, H. Gram, F. Di Padova, B. Huang, L. New, and R.J. Ulevitch MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha Science 295 2002 1291 1294
25. A.T. Saurin, J.L. Martin, R.J. Heads, C. Foley, J.W. Mockridge, and M.J. Wright The role of differential activation of p38-mitogen-activated protein kinase in preconditioned ventricular myocytes FASEB J. 14 2000 2237 2246
26. J.L. Martin, M. Avkiran, R.A. Quinlan, P. Cohen, and M.S. Marber Antiischemic effects of SB203580 are mediated through the inhibition of p38alpha mitogen-activated protein kinase: Evidence from ectopic expression of an inhibition-resistant kinase Circ. Res. 89 2001 750 752
27. N. Maulik, T. Yoshida, Y.L. Zu, M. Sato, A. Banerjee, and D.K. Das Ischemic preconditioning triggers tyrosine kinase signaling: a potential role for MAPKAP kinase 2 Am. J. Physiol. 275 1998 H1857 H1864
28. A.S. Clanachan, J.S. Jaswal, M. Gandhi, D.A. Bottorff, J. Coughlin, and B.A. Finegan Effects of inhibition of myocardial extracellular-responsive kinase and P38 mitogen-activated protein kinase on mechanical function of rat hearts after prolonged hypothermic ischemia Transplantation 75 2003 173 180
29. M. Yada, A. Shimamoto, C.R. Hampton, A.J. Chong, H. Takayama, and C.L. Rothnie FR167653 diminishes infarct size in a murine model of myocardial ischemia-reperfusion injury J. Thorac. Cardiovasc. Surg. 128 2004 588 594
30. D.A. Gorog, M. Tanno, X. Cao, M. Bellahcene, R. Bassi, and A.M. Kabir Inhibition of p38 MAPK activity fails to attenuate contractile dysfunction in a mouse model of low-flow ischemia Cardiovasc. Res. 61 2004 123 131
31. M.E. Noble, J.A. Endicott, and L.N. Johnson Protein kinase inhibitors: insights into drug design from structure Science 303 2004 1800 1805
32. R.J. Gum, M.M. McLaughlin, S. Kumar, Z.L. Wang, M.J. Bower, and J.C. Lee Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket J. Biol. Chem. 273 1998 15605 15610
33. K. Godl, J. Wissing, A. Kurtenbach, P. Habenberger, S. Blencke, and H. Gutbrod An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proc. Natl. Acad. Sci. USA 100 2003 15434 15439
34. F.V. Lali, A.E. Hunat, S.J. Turner, and B.M.J. Foxwell The pyridinyl imidazole inhibitor SB203580 blocks phophoinositide-dependent protein kinase activity, protein inase B phosphorylation and retinobalstoma hyperphosphorylation in interleukin-2-stimulated T cells independently of p38 Mitogen-activated protein kinase J. Biol. Chem. 275 2000 7395 7402
35. A.G. Borsch-Haubold, S. Pasquet, and S.P. Watson Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059 - SB 203580 also inhibits thromboxane synthase J. Biol. Chem. 273 1998 28766 28772